BERLIN, Germany and SEATTLE, Dec. 13, 2005 (PRIMEZONE) -- Epigenomics AG (Frankfurt, Prime Standard: ECX) (Other OTC:EPGNF), a molecular diagnostics company developing tests based on DNA methylation, announced today that they have reached agreement with Roche Diagnostics to postpone the milestone and licensing decision that was originally envisaged for November 2005 until the end of January 2006. Until then, Roche Diagnostics continues to have an option to obtain world wide exclusive rights to the breast cancer relapse prediction (Tamoxifen) / breast cancer molecular classification test from Epigenomics for an undisclosed milestone payment.
Significant amounts of additional data have been generated since the end of October following the reported inconclusive clinical validation study. Both partners wish to evaluate these most recent findings alongside the fully analyzed data set on the training, transfer and testing phase studies.
The postponing of a decision on the breast cancer test is independent of the colon cancer screening test milestone, which Epigenomics still expects to be agreed upon by both partners by the end of 2005.
END OF AD HOC
About Epigenomics
Epigenomics is a molecular diagnostic company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.